Mizuho analyst Salim Syed raised the firm’s price target on Biogen to $340 from $315 and keeps a Buy rating on the shares. The analyst updated the firm’s model post the Q1 results. The analyst now estimates Ocrevus worldwide peak sales of $8B in 2025, up from $7.5B previously.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB: